FRACTIONATION OF SERUM PROTEINS IN HYPERPROTEINEMIA, WITH SPECIAL REFERENCE TO MULTIPLE MYELOMA [PDF]
, 1941 Alexander B. Gutman +4 more
openalex +1 more source
Boron‐Based Functionalities Enhance the Potency of 2,5‐Dimethylfuran‐Based IDO1 Inhibitors
ChemBioChem, EarlyView.Indoleamine‐2,3‐dioxygenase‐1 (IDO1), a key immunoregulatory enzyme, is inhibited by novel boron derivatives (closo‐1,2‐ and 1,7‐carborane, boronic acids and esters, and benzoxaboroles) of 2,5‐dimethylfuran, each displaying low μM affinity for the human recombinant enzyme.
Thomas J. C. Carraro +4 more
wiley +1 more source
A New Conceptual Framework for the Therapy by Optimized Multidimensional Pulses of Therapeutic Activity. The case of Multiple Myeloma Model [PDF]
arXiv, 2017 We developed simulation methodology to assess eventual therapeutic efficiency of exogenous multiparametric changes in a four-component cellular system described by the system of ordinary differential equations. The method is numerically implemented to simulate the temporal behavior of a cellular system of multiple myeloma cells.
arxiv
Chromenone derivatives as CRM1 Inhibitors for Targeting Glioblastoma
ChemBioChem, Accepted Article.Glioblastoma (GBM) is one of the most aggressive and deadly cancers. Due to the complexity and redundancy within signaling networks in GBM, targeted inhibitors of specific pathways have shown only limited success. The nuclear export receptor Chromosome Region Maintenance 1 (CRM1) has recently emerged as a promising therapeutic target, as its inhibition
Wolfgang Link +10 more
wiley +1 more source
Experimental and Molecular Medicine, 2018 Experimental & molecular medicine Researchers may have found a new target for treatment of multiple myeloma (MM), a common type of blood cancer.
Lili Zhou +7 more
doaj +1 more source
Prediction of cancer dynamics under treatment using Bayesian neural networks: A simulated study [PDF]
arXivPredicting cancer dynamics under treatment is challenging due to high inter-patient heterogeneity, lack of predictive biomarkers, and sparse and noisy longitudinal data. Mathematical models can summarize cancer dynamics by a few interpretable parameters per patient.
arxiv
MULTIPLE MYELOMA. IV. ABNORMAL SERUM COMPONENTS AND BENCE JONES PROTEIN 1 [PDF]
, 1951 R. Wayne Rundles +2 more
openalex +1 more source
A VH4-34+ myeloma protein with weak autoreactivity
Haematologica, 2007 It has been suggested that VH4-34 gene segment expression is counter-selected in multiple myeloma (MM) due to a self-tolerance mechanism. We cloned and sequenced a VH4-34 gene segment from bone marrow mononuclear cells of a stage III MM patient. We show that VH4-34 was expressed by the serum IgA myeloma (M)-protein, as demonstrated by reactivity with ...
Keith M. Thompson +5 more
openaire +4 more sources
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Clinical Pharmacology &Therapeutics, EarlyView.The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
STUDIES IN SERUM ELECTROLYTES. XV. THE CALCIUM-BINDING PROPERTY OF THE SERUM PROTEINS (MULTIPLE MYELOMA, LYMPHOGRANULOMA VENEREUM AND SARCOIDOSIS) [PDF]
, 1948 Arnold J. Rawson, F. William Sunderman
openalex +1 more source